Pja2 (NM_144859) Mouse Tagged ORF Clone Lentiviral Particle
CAT#: MR209720L4V
- LentiORF®
-
Lenti ORF particles, Pja2 (GFP-tagged) - Mouse praja 2, RING-H2 motif containing (Pja2), transcript variant 2, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 12,540.00
货期*
详询
规格
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (3)
Specifications
Product Data | |
Product Name | Pja2 (NM_144859) Mouse Tagged ORF Clone Lentiviral Particle |
Synonyms | AI447901; AL022700; mKIAA0438; Neurodap1 |
Vector | pLenti-C-mGFP-P2A-Puro |
ACCN | NM_144859 |
ORF Size | 1935 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(MR209720).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_144859.2, NP_659108.1 |
RefSeq Size | 4520 bp |
RefSeq ORF | 1938 bp |
Locus ID | 224938 |
Gene Summary | Has E2-dependent E3 ubiquitin-protein ligase activity. Responsible for ubiquitination of cAMP-dependent protein kinase type I and type II-alpha/beta regulatory subunits and for targeting them for proteasomal degradation. Essential for PKA-mediated long-term memory processes. Through the ubiquitination of MFHAS1, positively regulates the TLR2 signaling pathway that leads to the activation of the downstream p38 and JNK MAP kinases and promotes the polarization of macrophages toward the pro-inflammatory M1 phenotype.[UniProtKB/Swiss-Prot Function] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
Customer
Reviews
Loading...